Industries > Pharma > Global Anti-Obesity Drugs Market Forecast 2018-2028

Global Anti-Obesity Drugs Market Forecast 2018-2028

Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

PUBLISHED: 20 November 2018
PAGES: 250
PRODUCT CODE: PHA0343
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0343 Categories: , Tags: , , ,

The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1% from 2017 to 2022. In 2017, the prescription drugs submarket held 96% of the global anti-obesity drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 119 tables and 139 figures– all unavailable elsewhere.

The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Anti-obesity Drugs Market forecast from 2018-2028

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:
• Incretion mimetics/GLP-1 agonists
• SNDRIs
• Lipase Inhibitors
• Serotonin receptor agonists
• Sympathomimetic-GABA receptor agonists
• Sympathomimetics

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy:
• Long-term Drugs
• Short-term Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs:
• Innovator
• Generic Drugs

• Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC:
• Prescription Drugs
• OTC

• This report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs:
• Saxenda
• Contrave/Mysimba
• Belviq
• Qysmia
• Xenical
• Alli

Global Anti-Obesity Drugs Market Forecast 2018-2028

• This report provides individual revenue forecasts from 2018-2028 for these regional and national markets:
• US
• Japan
• EU5: Germany, France, Spain, Italy, UK
• BRIC: Brazil, Russia, China, India
• RoW

Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs

• Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market:
• Eisai/Arena
• GlaxoSmithKline (GSK)
• Novo Nordisk
• Orexigen/Takeda
• Roche
• Teva
• Vivus

• This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.

• This report gives an overview of pricing and reimbursement in the US and EU.

• This report provides a SWOT Analysis of the global anti-obesity drugs market.

Visiongain’s study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.

Buy our report today Anti-obesity Drugs Market Analysis : Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Anti-Obesity Drugs Market Forecast 2018-2028


Latest Pharma news

Visiongain Publishes Pharmaceutical Product Information Management System Market Report 2020-2030

Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.

19 October 2020

READ

Visiongain Publishes Pulmonary/Respiratory Drug Delivery Market Report 2020-2030

The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.

12 October 2020

READ

Visiongain Publishes Real-World Evidence (RWE) Solutions Market Report 2020-2030

We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

02 October 2020

READ

Visiongain Publishes mRNA Vaccines Market Report 2021-2031

The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.

02 October 2020

READ

Categories

Category